Last day of trading in warrants of series T04 is April 22, 2021

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

Hørsholm, Denmark, April 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") announces that Thursday, April 22, 2021 is the last day of trading in warrants of series T04. The exercise period for warrants of series T04 runs to and includes Monday, April 26, 2021. Each three (3) warrants gives the right to subscribe for one (1) new share in ExpreS2ion. The exercise price is SEK 22.00 per share.

Summarized terms for the warrants of series T04

• Subscription period: April 12 – April 26, 2021

• Issue size: 5,455,297 warrants of series TO4, which entitles to subscription of 1,818,432 shares. If all the warrants are exercised, The Company will receive approximately SEK 40.0 million before issuing costs.

• Exercise price: SEK 22.00 per share

• Last day for trading warrants of series TO4: April 22, 2021

• Dilution etc.: If all warrants are exercised the share capital will increase with SEK 202,048, from SEK 3,067,589 to SEK 3,269,637. If all warrants are exercised the number of shares will increase with 1,818,432 shares, from 27,608,301 shares to 29,426,733 shares. The dilution at the exercise of all warrants amounts to 6.2% percent of the number of shares and number of votes.

Note that the warrants that are not exercised at the latest April 26, 2021, or sold at the latest April 22, 2021, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

Also please note that certain nominees might close their applications earlier than April 26, 2021.

How warrants are exercised

• Nominee-registered warrants (Custody account) – Subscription and payment by the exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

• Direct-registered warrants (Securities account) – No issue report nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.

The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Additional information can be found in the attached file, T04 Subscription Brochure.

The application form including instructions for payment will be available at ExpreS2ion’s investor relations website, investor.expreS2ionbio.com and Arctic Securities website (www.arctic.com/secse).

Advisors

Arctic Securities AS, filial Sverige is the financial advisor and issuing agent to the Company regarding the warrants.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: [email protected]